Two-year survival correlates with CD94 1A and TCR rearrangement
. | Died before 2 y . | Alive after 2 y . | P . |
|---|---|---|---|
| No. of cases | 9 | 12 | |
| Median age, y | 29 | 17 | .11 |
| Sex, n male:female | 6:3 | 7:5 | .70 |
| CD161, n/total | 2/9 | 9/12 | .02 |
| CD44, n/total | 2/9 | 7/12 | .11 |
| E2A, n/total | 4/7 | 5/12 | .52 |
| c-ID2, n/total | 5/8 | 3/12 | .11 |
| TCF-1, n/total | 3/7 | 7/11 | .39 |
| CD94 1A, n/total | 0/9 | 7/12 | .01 |
| CD94 1B, n/total | 0/9 | 2/12 | .21 |
| KIR 2DL4, n/total | 0/9 | 1/12 | .38 |
| KIR 2D, n/total | 1/9 | 1/12 | .81 |
| KIR 3D, n/total | 2/9 | 6/12 | .20 |
| T-cell receptor, n/total | 8/9 | 3/12 | .01 |
| LDH, IU/L | 586 | 456 | .19 |
| Blasts in blood, n/total | 3/9 | 5/11 | .59 |
| WBC count, 103/μL | 7.1 | 7.3 | .64 |
| HB level, g/dL | 11 | 13.2 | .22 |
| PLT count, 103/μL | 255 | 194 | .35 |
| Mediastinal mass, n/total | 4/9 | 5/12 | .90 |
| Stage IV, n/total | 5/9 | 7/12 | .89 |
| ALL-like regimens, n/total | 1/9 | 6/12 | .07 |
. | Died before 2 y . | Alive after 2 y . | P . |
|---|---|---|---|
| No. of cases | 9 | 12 | |
| Median age, y | 29 | 17 | .11 |
| Sex, n male:female | 6:3 | 7:5 | .70 |
| CD161, n/total | 2/9 | 9/12 | .02 |
| CD44, n/total | 2/9 | 7/12 | .11 |
| E2A, n/total | 4/7 | 5/12 | .52 |
| c-ID2, n/total | 5/8 | 3/12 | .11 |
| TCF-1, n/total | 3/7 | 7/11 | .39 |
| CD94 1A, n/total | 0/9 | 7/12 | .01 |
| CD94 1B, n/total | 0/9 | 2/12 | .21 |
| KIR 2DL4, n/total | 0/9 | 1/12 | .38 |
| KIR 2D, n/total | 1/9 | 1/12 | .81 |
| KIR 3D, n/total | 2/9 | 6/12 | .20 |
| T-cell receptor, n/total | 8/9 | 3/12 | .01 |
| LDH, IU/L | 586 | 456 | .19 |
| Blasts in blood, n/total | 3/9 | 5/11 | .59 |
| WBC count, 103/μL | 7.1 | 7.3 | .64 |
| HB level, g/dL | 11 | 13.2 | .22 |
| PLT count, 103/μL | 255 | 194 | .35 |
| Mediastinal mass, n/total | 4/9 | 5/12 | .90 |
| Stage IV, n/total | 5/9 | 7/12 | .89 |
| ALL-like regimens, n/total | 1/9 | 6/12 | .07 |